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A B S T R A C T
Introduction. Peyronie’s disease (PD) can be emotionally and sexually debilitating for patients and may negatively
impact partner relationships.
Aims. This study aims to present an ongoing collaborative care model for patients with PD and to discuss the critical
need for integration of patient care among sexual medicine physicians and mental health practitioners or sex
therapists.
Methods. PubMed searches using the terms “Peyronie’s disease” and “natural history,” “treatment,” “psychosexual,”
“depression,” “relationship,” and “partner” were conducted. Expert opinion based on review of the relevant pub-
lished literature and clinical experience was used to identify meaningful treatment targets for patients with PD within
a collaborative care model.
Main OutcomeMeasure. Characteristics of PD, medical treatment, and important assessment and treatment targets,
including physical, emotional, psychosexual, and relationship concerns, from peer-reviewed published literature and
clinical experience.
Results. PD can result in signiﬁcant patient and partner distress and relationship disruption. Sex therapy interven-
tions may be directed at acute emotional, psychosexual, and relationship problems that occur during the initial
diagnosis of PD, the period following minimally invasive or surgical treatment for PD, or recurring problems over
the lifelong course of the disease. Sex therapy to improve self-acceptance, learn new forms of sexual intimacy, and
improve communication with partners provides comprehensive treatment targeting emotional, psychosexual, and
relationship distress. Ongoing communication between the mental health practitioner and physician working with
the patient with PD about key assessments, treatment targets, and treatment responses is necessary for coordinated
treatment planning and patient care.
Conclusions. Men with PD are more likely now than in the past to see both a sexual medicine physician and a mental
health practitioner or sex therapist, and the integration of assessments and treatment planning is essential for optimal
patient outcomes. Hartzell R. Psychosexual symptoms and treatment of Peyronie’s disease within a collab-
orative care model. Sex Med 2014;2:168–177.
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Introduction
Peyronie’s disease (PD) is an acquired benignyet debilitating condition characterized by the
development of dense ﬁbrous collagens plaques in
the tunica albuginea of the penis [1]. The plaques
prevent normal expansion of the tunica albuginea
during erection, resulting in various possible
altered penile shapes, such as curvature deformity,
shortening, and narrowing with a hinge effect [1].
The etiology and underlying pathophysiology of
PD are not completely understood. However, PD
is thought to originate from trauma or repeated
microtrauma to the erect penis in genetically sus-
ceptible men [2]. Early studies proposed that PD
was a rare condition, with a prevalence of <1%;
however, later studies have shown that PD is more
common, with up to 7.1% of men affected in the
general population [3–12]. Prevalence estimates
are higher in selected populations, ranging from
8.1% in patients with type 2 diabetes mellitus
(DM) [11] to 20.3% in the presence of comorbid
DM and erectile dysfunction (ED) [10].
PD can be emotionally and sexually debilitat-
ing for patients and may negatively impact
partner relationships [13–16]. The altered penile
shape that patients with PD may experience can
prevent intercourse or result in patient bother,
greater awkwardness, performance anxiety, less
sexual enjoyment, and reduced overall sexual sat-
isfaction. The current article reviews the natural
history of the disease course of PD, psychosexual
consequences of PD, and current medical treat-
ment options for patients with PD. In response
to psychosexual consequences and treatment of
PD, men with PD are more likely now than in
the past to see both a sexual medicine physician
and a mental health practitioner or sex therapist.
The current article also presents and discusses an
ongoing collaborative biopsychosocial model in
which patients with PD are seen by a mental
health practitioner and a physician as part of
patient management. The model emphasizes
ongoing, effective communication that allows an
integration of assessments and treatment plan-
ning for optimal patient care.
The Natural History of PD
Understanding the natural history of PD supports
effective communication and collaboration
between the sex therapy mental health practitioner
and the sexual medicine physician. Several studies
have demonstrated that for most patients, PD is a
sustained or progressive disease [13,17,18]. When
penile curvature is present early in the disease, it
tends to stabilize or worsen, with one study
showing a mean change in curvature of 22° during
the natural course of disease [18]. Decreased
stretched, ﬂaccid penile length (0.8 cm mean
change in length) has also been shown over 18
months [18]. In addition to being a chronic disease
for many patients, the disease course is highly vari-
able, and the outcome of PD is uncertain.
PD has two phases, acute and chronic, both of
which are distinguished by symptom presentation.
In the acute phase, the penile plaque is new and
still forming, with associated inﬂammation. The
patient may present with one or more symptoms,
including painful erections, a palpable plaque, and
curvature of the erect penis. Not all patients with
PD experience penile pain or discomfort, but for
those patients who do experience pain, it usually
resolves by 12–18 months after disease onset [18].
During the acute phase, the patient’s penile shape
may be changing, requiring adjustments from the
patient and the patient’s partner. The patient may
begin to experience anxiety and negative self-
perceptions related to sexual performance, and
sexual function and the partner relationship may
be disrupted.
Younger patients may be particularly vulnerable
to emotional, psychosexual, and relationship
bother/distress and may beneﬁt from integrated
care with a sex therapy mental health practitioner
and sexual medicine physician. Approximately
10% of patients who present with PD are younger
than age 40, including teenagers [10,17,19–21].
Younger patients are more likely to present to a
physician during the acute phase of PD, typically
within 3 months from the onset of symptoms, with
the presenting symptoms of pain during erection,
palpable nodules, and changing penile shape
[20,22]. Additionally, progressive worsening of an
altered penile shape may be more likely in patients
younger than age 50 [17,23]. Younger patients are
more likely to seek treatment sooner, have more
than one palpable penile plaque, and present with
cardiovascular risk factors, such as DM [19].
The second phase of PD, the chronic disease
phase, begins approximately 12–18 months follow-
ing disease onset. Pain and inﬂammation typically
resolve, and the penile plaque and changing penile
shape become relatively stable. During the chronic
phase, the penile curvature may continue to
worsen in some patients; it rarely improves during
this phase [18]. In addition to emotional, psycho-
sexual, and relationship concerns associated with
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chronic PD, patients in the chronic phase may
experience anxiety related to surgical treatment
options and possible complications, including PD
recurrence.
PD Treatments
The symptoms of PD can be medically managed
usingminimally invasive therapies or surgical inter-
vention in appropriate patients; however, currently
there is no cure for PD. Pharmacological treat-
ments and minimally invasive approaches may be
considered for patients early in the disease course
[24]. Currently available therapies include oral sys-
temic agents, iontophoresis, shockwave therapy,
traction therapy, and intralesional injections.
Intralesional injection of collagenase clostridium
histolyticum (CCH; Xiaﬂex®, Auxilium Pharma-
ceuticals, Inc., Chesterbrook, PA, USA) is the only
U.S. Food and Drug Administration (FDA)-
approved treatment for men with PD. Most of the
existing pharmacological and otherminimally inva-
sive treatment regimens have not demonstrated
consistent results in clinical trials [25–27]. A few
treatments have shown signiﬁcantly decreased
penile curvature in placebo-controlled studies,
including intralesional injection with interferon
(IFN)α-2b; however, additional anti-inﬂammatory
medications may be required with this agent due to
side effects, which may limit its use. CCH has also
demonstrated efﬁcacy and tolerability in two iden-
tical Phase 3 clinical studies [28–33] and has been
approved by theU.S. FDA for use in adultmenwith
PD with a palpable plaque and a curvature defor-
mity of 30 degrees or greater at the start of therapy.
Treatment with IFN α-2b or CCH requires physi-
cian administered injections directly into the penile
plaque. IFN α-2b is administered as a biweekly
injection over a period of 6–12 weeks and may
result inmild tomoderate adverse effects, including
myalgias, arthralgias, sinusitis, ﬂu-like symptoms
with fever and chills, and minor penile swelling
[29–31]. CCH is administered as two injections
separated by 24–72 hours and repeated after 6
weeks, for up to four treatment cycles [28]. Follow-
ing the second injection of each treatment cycle,
modeling—this involves gradual, gentle stretching
of the ﬂaccid penis in the opposite direction of the
penile curvature—is used to further reduce the
restrictive effects of the plaque. Adverse effects are
transient andmost commonly include injection site
tenderness, edema, pain, and bruising, and serious
adverse events include rare cases of corporal
rupture [28,33].
Surgical procedures typically are not considered
until patients are within the chronic phase of PD,
show stable disease for ≥12 months, or have intrac-
table ED [26,27]. Surgical treatment is invasive,
and as a result, it is often limited to patients with
severe ED and/or a penile shape or level of rigidity
that does not allow sexual activity. Surgical treat-
ments to correct the penile curvature include short-
ening the longer side (known as tunical plication
corporoplasty) without intervention on the side of
the penis with the plaque, tunical lengthening that
targets the restricting effects of the plaque through
plaque incision or excision with potential use of
graftingmaterials, or implanting a penile prosthesis
with or without straightening maneuvers
[26,27,34]. Potential complications associated with
surgery include penile shortening, risk of sensation
changes, recurrence of penile curvature, and subse-
quent ED [35,36]. Possible penile prosthetic
implantation complications include device break-
down or failure, recurrent curvature, penile short-
ening, malposition, infection, erosion, and urethral
injury [35–38].
The medical management of PD with mini-
mally invasive treatment and surgical treatment
options may address some of the physical symp-
toms of PD. However, optimal patient manage-
ment in the integrated care model requires
assessment and treatment of emotional, psycho-
sexual, and relationship concerns associated with
PD to achieve the most favorable quality-of-life
outcomes for patients. Additionally, mental health
practitioners within the integrated care model are
particularly well suited to the pretreatment or
presurgical assessment of patient beliefs and
expectations about treatment outcomes. Several
long-term follow-up studies have indicated that
moderate-to-high levels of dissatisfaction can
occur among patients receiving surgery [36,39–
41]. Given the potential complications and pos-
sible recurrence of disease following surgery, the
assessment of patient expectations and beliefs
about the surgical procedure and the identiﬁcation
and correction of inaccurate beliefs are essential
components to presurgical patient management
[41–44].
Emotional, Psychosexual, and
Relationship Concerns
Assessment of the emotional, psychosexual, and
relationship aspects of the patient’s PD symptoms
that negatively impact the patient’s quality of life is
needed to prioritize treatment goals. Although
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severe penile curvature >60° has been identiﬁed as
an independent predictor of sexual difﬁculties in
patients with PD [45], the full impact of PD on
patients is multifaceted and is not necessarily
related to the severity of penile curvature. Patients
with lesser severities of curvature may have signiﬁ-
cant bother or distress associated with their
disease. A qualitative study of the psychosocial
outcomes for patients with PD identiﬁed six core
domains important to men with PD, including
concerns about physical appearance, sexual self-
image, loss of sexual conﬁdence and feelings of
attractiveness, sexual function and performance,
performance anxiety and concern about not satis-
fying partners sexually, and social stigmatization
and isolation [16]. Importantly, it was found that
the level of concern within these domains was uni-
formly high, despite a wide range in the degree of
penile curvature among the patients studied.
Assessment of the psychosexual impact of PD
using the PD-speciﬁc Peyronie’s Disease Ques-
tionnaire, a validated, patient-reported measure,
has conﬁrmed that high PD symptom bother can
occur across the full range of mild, moderate, and
severe penile curvature [46]. Quality-of-life factors
beyond penile curvature, including psychosexual
and relationship factors, can impact a patient’s per-
ception of his PD [13].
Emotional Concerns
The emotional state of the patient may have
important interactions with his psychosexual and
relationship concerns, and areas of bother or emo-
tional distress may be an important treatment
target for the patient with PD (Table 1). A review
of discussion group themes from PD Internet dis-
cussion boards aimed at supporting patients with
PD and their partners identiﬁed patients’ feelings
of anger, depression, fear of rejection, and dimin-
ished self-worth, which led to feelings of isolation
and an avoidance of intimacy as important discus-
sion themes [47]. In a survey of men with PD, 77%
of patients acknowledged psychological effects due
to PD, and 55% of patients reported these effects
persisted over time [13]. A study evaluating
depression and quality of life in patients with PD
found that 48% of patients had clinically meaning-
ful depression, with 26% of these patients report-
ing moderate depressive symptoms and 21%
reporting severe depressive symptoms [15]. Of the
patients who reported being depressed at baseline,
58% remained depressed after the 18-month
follow-up period, suggesting that rather than
adjust to PD symptoms, patients’ depressive symp-
toms persisted [15]. In a younger, teenage cohort
with PD, high distress was reported by 94% of
patients, 34% sought treatment for anxiety/mood
disorders, and 28% had a negative experience with
a sexual partner related to PD [21].
In addition to depressive symptoms, patients
with PD may experience loneliness or hopeless-
ness, and a partner’s level of support, or positive or
negative reactions, can inﬂuence the patient’s feel-
ings of isolation [16]. Feelings of isolation and
social stigmatization were found to be greater
during the early phase of PD before coping
mechanisms or trusted support had developed, but
the feelings did not resolve over the course of PD
[16]. Feelings of shame and inadequacy due to PD
have been reported and coincided with low self-
esteem in some men [16]. Additionally, body
image issues can be a source of high distress in
patients with PD. Patients may experience aes-
thetic concerns, even if penile functioning is
normal, about how the penis looks and feels. This
concern may have the greatest impact particularly
on homosexual patients with PD, as there can be a
constant comparison with the partner’s penis. The
one available study examining men who have sex
with men (MSM) who sought treatment for PD
found that 92.9% of MSM reported they were
self-conscious about the appearance of their penis
and 92.9% were not satisﬁed with the size of their
penis [48]. Changes in penile shape are not neces-
sary for body image concerns, as loss of penile
girth or length have been reported to be just as
distressing as more severe disﬁgurements, and
some men did not like to look at or touch their
penis [16]. The possibility of body dysmorphia is
further suggested by a study showing 54% of men
with PD overestimated their degree of penile cur-
vature, and 44% overestimated their curvature by
≥20° [49]. Similarly, in one study of postsurgical
penile measurement, over half of the patients com-
plained of penile shortening, despite the fact that
Table 1 Call out box highlighting important components
of Peyronie’s disease (PD)-associated patient emotional
distress that may be appropriate targets for treatment
PD-associated emotional distress treatment targets
Depression
Anger
Body image dysmorphia
Diminished self-worth
Feelings of shame and inadequacy
Feelings of isolation
Fear of rejection
Avoidance of intimacy
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the objectively measured mean penile length
increased by 2.1 cm [50].
Psychosexual Concerns
Psychosexual concerns of the patient with PD may
overlap with his emotional state and affect his rela-
tionship with his sexual partner, and thus they are
an important area of assessment and treatment
(Table 2). A patient’s anxiety about sex may
include concern about hurting his partner during
intercourse or further injuring his penis [16]. Pain
during sex due to penile curvature, for the patient
and/or the patient’s partner, may be a signiﬁcant
contributor to sexual dysfunction experienced by
men with PD and their partners. The contribution
of pain to psychosexual concerns and sexual func-
tion varies, depending on the severity of the
altered penile shape, the duration of PD, and the
position of intercourse [16]. Moreover, sexual dif-
ﬁculties may exist independent of the patient’s
physical ability to engage in intercourse due to an
altered penile shape. In a study of men with PD,
most men were able to engage in penetrative sex;
however, many said that intercourse could not be
natural or spontaneous [16]. The men described
their sexual function as impaired due to difﬁculties
with speciﬁc sex positions, reduced ability to ejacu-
late, loss of erection, decreased satisfaction, or pain
during intercourse [16]. Some men refrained from
sex, despite being able to physically engage in
vaginal intercourse, due to psychological or inter-
personal effects of PD, and many men had with-
drawn from all forms of sexual interaction [16].
Men with partners were less likely to initiate sex,
and single men avoided dating [16].
Relationship Concerns
If the patient’s and sexual partner’s reaction to PD
symptoms is negative, relationship concerns may
become a target of treatment (Table 3). In a small
study of MSM who sought treatment for PD, 45%
of MSM and 64% of non-MSM reported their
intimate relationships were negatively affected by
PD [48]. Relationship and emotional concerns
related to PD have been shown to inﬂuence one
another. In a study of men with PD, the prevalence
rates of emotional and relationship problems
attributable to PD were 81% and 54%, respec-
tively [14]. Among these men, relationship prob-
lems were independently associated with
emotional problems and the ability to have inter-
course, and relationship problems and loss of
penile length signiﬁcantly and independently pre-
dicted emotional problems. Relationship concerns
associated with PD occur in single men as well as
partnered men and may require different treat-
ment focus. In single patients, PD symptoms may
result in fear of starting a relationship and avoid-
ance of dating. Discussion group themes from PD
discussion board websites showed that single and
divorced men avoided intimacy, as they were afraid
that their PD would become fodder for gossip
among the social networks of women whom they
dated [47]. The fear of such potential gossip
resulted in feelings of shame and loss of control
over their personal life.
For couples, potential patient and partner con-
cerns include performance anxiety and concern
about satisfying their partner [16]. Additionally,
conﬂicting or unbalanced sexual desires between
partners, lack of emotional support or understand-
ing, withdrawal of the partner, and loss of intimacy
may be important treatment targets. The couple
may experience boredom with a limited number of
sexual positions that they can engage in due to
penile curvature. The partner may experience feel-
ings of helplessness and personal responsibility,
especially if the PD developed after an injury
during sexual intercourse, and frustration at the
Table 2 Call out box highlighting important components
of Peyronie’s disease (PD)-associated patient
psychosexual concerns that may be appropriate targets
for treatment
PD-associated psychosexual treatment targets
Loss of sexual confidence
Lack of sexual desire or sexual aversion
Decreased sexual satisfaction
Difficulty with specific sex positions
Sexual performance anxiety
Concern about further penis injury
Aesthetic concerns: how the penis looks and feels
Avoidance of dating
Table 3 Call out box highlighting important components
of Peyronie’s disease (PD)-associated patient and partner
relationship concerns that may be appropriate targets for
treatment
PD-associated relationship treatment targets
Concern about not sexually satisfying partner
Concern about hurting partner during sex
Conflicting or unbalanced sexual desires
Lack of emotional support or withdrawal of the partner
Loss of intimacy
Boredom with limited sexual positions due to penile curvature
Partner feelings of helplessness
Partner feelings of personal responsibility
Partner frustration with patient’s fixation on altered penile shape
Partner sexual dysfunction
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PD patient’s obsession or focus on the altered
shape of his penis. Partners themselves may begin
to experience sexual dysfunction requiring inter-
vention [15,51].
Given the breadth of emotional, psychosexual,
and relationship concerns that patients with PD
may experience, and the high level of distress or
bother that may be associated with such concerns,
sex therapy aimed at improving sexual communi-
cation and satisfaction within the context of PD
symptoms and functional constraints is essential
for patients and their partners. Consistent with the
integrative model of sex therapy and sexual medi-
cine, patients who receive timely information and
reassurance about PD and its treatment options,
particularly interventions that address sexual func-
tioning and penile shortening, may be more likely
to experience less distress and an improved quality
of life [14]. In a study not speciﬁc to men with PD,
greater sexual satisfaction and functioning in men
was associated with greater self- and partner dis-
closure about sexual preferences, a skill that can be
developed in sex therapy and applied to improving
the relationship functioning of men with PD with
their partners [52].
Treatment Goals
It is often assumed that successful medical treat-
ment that leads to resolution of PD penile
curvature would alleviate psychosexual and rela-
tionship concerns. However, one study suggests
resolution of physical symptoms may not auto-
matically lead to such a cascade of improvements.
In this study, successful and satisfying surgical
outcomes for patients with congenital penile cur-
vature did not improve personal relationships
or psychogenic ED [53]. These ﬁndings support
the need for an integrated, collaborative care
model, which incorporates sex therapy, targeted
to emotional, psychosexual, and relationship
factors, in collaboration with sexual medicine
interventions for optimal patient outcomes.
Ongoing assessment of patient function and
response to treatment is important, as treatment
targets in any one area of concern may inﬂuence
patient function in other areas of concern. There-
fore, patient function and concerns may shift
during sexual medicine interventions involving
minimally invasive or surgical treatments. Promo-
tion of effective communication about sex and
learning techniques to improve sexual function to
overcome limitations imposed by PD symptoms
may positively and broadly affect emotional con-
cerns of the patient in addition to psychosexual
and relationship concerns.
Treatment goals in sex therapy are addressed
through individual, couples, and group therapy
(see Table 4). Individual therapy is appropriate for
patients without a current sexual partner or for
patients with a sexual partner who may have per-
sonal treatment goals in addition to goals involv-
ing their partner. Individual therapy addresses
self-image/body image problems, depression, self-
acceptance, reframing the symptoms of PD and
their associated effects on sexuality and quality of
life, and development of effective coping skills to
manage anxiety and frustration. Couples therapy
additionally addresses psychosexual concerns,
relationship distress, and expansion of the deﬁni-
tions of intimacy and sex. Couples learn to explore
nonintercourse sexual activities/creativity, and
through improved communication and trust,
couples determine what sexual satisfaction means
Table 4 Call out box highlighting therapeutic approaches to address Peyronie’s disease (PD)-associated treatment
targets
Treatment
approach Targeted solutions
Individual
therapy
Self-acceptance targeting self-image/body image
Reframing the symptoms of PD to help the patient reinterpret effects of PD symptoms on sexuality and quality of life
Development of effective coping skills to manage negative emotions
Couples
therapy
Expansion of the couple’s definitions of intimacy and sex
Exploration of nonintercourse sexual activities/creativity
Improved communication about sex to further develop trust
Determination of what sexual satisfaction means for the patient and partner
Development of alternative methods for achieving sexual satisfaction
Group
therapy
Providing social support among patients with PD coping with similar issues to reduce feelings of isolation and negative
emotions
Providing social support among partners of patients with PD coping with similar issues to reduce feelings of isolation and
negative emotions
Learning effective coping skills from other patients with PD or their partners
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for the patient and partner. Additionally, they may
learn alternative methods for achieving sexual sat-
isfaction, given limitations imposed by PD symp-
toms. Group therapy, either in-person or online,
can also signiﬁcantly reduce distress. Social
support can be gained through group therapy
among patients with PD coping with similar
issues, reducing feelings of isolation and assisting
in the development of effective coping skills. Fur-
thermore, these same issues can be addressed in
group therapy among the partners of patients with
PD. Patients should be made aware of Internet-
based resources, such as the sexual health discus-
sion forums dedicated to PD and coping with a
partner’s sexual health issues, which are available
at http://www.sexualmed.org.
Integration of Sex Therapy and Sexual Medicine:
A Collaborative Care Model
The integration of sex therapy and sexual medicine
in the evaluation and treatment of patients with PD
addresses the physical aspects of patient sexual
function as well as the patient’s sexual beliefs and
expectations. In addition, emotional, psychosexual,
and relationship concerns may all contribute to
sexual difﬁculties and poor quality of life. Optimal
patient management necessitates a collaborative
working relationship between the patient’s mental
health practitioner and physician. An ongoing
dynamic collaborative model involving a mental
health practitioner and a physician working with
patients with PD is presented in Figure 1.
Sex Therapy Mental Health PracƟƟoner
PaƟent EvaluaƟon:
• Record paƟent core concerns
related to PD symptoms 
• Understand sexual beliefs and
expectaƟons 
• IdenƟfy emoƟonal,
psychosexual, and relaƟonship
funcƟoning  
Sexual Medicine Physician
PaƟent EvaluaƟon:
• Diagnose and idenƟfy phase of 
PD
• Record core physical 
symptoms
• Determine comorbid 
disorders
Sex Therapy Mental Health PracƟƟoner
Treatment Planning and ImplementaƟon: 
• Set individual or couples therapy 
goals
• Understand medical treatment 
expectaƟons and beliefs
• Review of procedures and 
potenƟal side eﬀects
Sexual Medicine Physician
Treatment Planning and ImplementaƟon: 
• Implement ongoing evaluaƟon 
and monitoring
• Review of minimally invasive and 
surgical treatments
CollaboraƟve Discussion
• Assess core outcomes
• PrioriƟze treatment 
targets and opƟons
CollaboraƟve Discussion
• Assess paƟent readiness 
for treatment opƟons
• Evaluate paƟent response 
to treatment
• Consider addiƟonal 
treatment targets and 
opƟons
Figure 1 A biopsychosocial collab-
orative model of the integration of
sex therapy and sexual medicine in
the treatment of patients with
Peyronie’s disease (PD).
174 Hartzell
Sex Med 2014;2:168–177 © 2014 The Author. Sexual Medicine published by Wiley Periodicals, Inc.
on behalf of International Society for Sexual Medicine.
In this model, from the time of initial referral to
the clinic, the patient with PD sees both the sexual
medicine physician and the sex therapy mental
health practitioner. Regular communication
between the mental health practitioner and the
physician about the patient regarding each provid-
er’s assessment of the patient’s current function
and difﬁculties and the development of coordi-
nated treatment planning is essential to the collab-
orative model. The frequency of follow-up visits
with the patient’s sexual medicine physician and
sex therapy mental health practitioner is deter-
mined by the assessment, treatment goals, and
treatment response of the patient. For patients
referred with a diagnosis of PD, the mental health
practitioner’s assessment of the diagnosis (e.g.,
when the diagnosis was received, how the assess-
ment of PD was done, and who provided the diag-
nosis), treatment history, the patient’s perspective
on response to previous treatments, and the
patient’s plans for future treatments provide valu-
able input to the physician’s assessment of the
patient’s medical needs. The physician’s treatment
regimen and prognoses for the patient can also
provide information regarding how the mental
health practitioner can be most helpful to the
patient’s understanding, treatment adherence, and
acceptance of his physical condition.
Sex therapy interventions may be directed at
acute emotional, psychosexual, and relationship
problems that occur during the initial diagnosis of
PD, the period following minimally invasive or
surgical treatment for PD, or recurring problems
over the lifelong course of the disease. Studies of
patients with PD who received surgical interven-
tions to correct penile curvature, or other changes
in penile shape and rigidity, support the need for a
presurgical evaluation of the patient’s readiness for
surgery [41–44]. Any inappropriate or inaccurate
expectations expressed by the patient during the
presurgical evaluation are then targeted for inter-
vention and are communicated to the physician
performing the surgery. The mental health prac-
titioner in the integrated collaborative care model
is well positioned to assess patient readiness and to
implement any needed interventions to improve
patient readiness.
As previously noted, counseling for patients
pursuing surgical intervention should address
patient expectations for penile straightening,
potential adverse events, and surgical recovery,
including if the patient has someone who can help
take care of him in the immediate postsurgery
period. Patient expectations for postsurgery reha-
bilitation, including possible massage and stretch
therapy, use of penile traction therapy, and refrain-
ing from sexual intercourse for 6 weeks, should
also be addressed [54]. For patients receiving
penile prosthetic implantation, speciﬁc counseling
topics should include discussion of the patient’s
feelings about the penile changes associated with
treatment and his understanding that eventually
the prosthesis will need to be replaced. Addition-
ally, patients will need to be counseled regarding
permanent changes to the structure of the penis
required with implantation, and they need to
understand that they will never again function
naturally without the help of an implant. For
patients not currently in a relationship, any patient
concerns or anxiety about whether and how the
patient would disclose that he has an implant to a
new partner should be discussed.
For patients receiving intralesional injection
therapy (CCH or interferon), counseling should
examine the patient’s understanding of the
repeated treatment cycles that occur over several
months and the time period for penile curvature
response, potential adverse effects, and the poten-
tial need to refrain from sexual intercourse follow-
ing treatment. Of additional concern from the
therapist’s perspective for patients receiving either
surgery or intralesional injections, is how the
patient’s expectations following treatment may
affect his relationship with his partner or potential
partners. For example, some patients may believe
that improvements following treatment may allow
them to initiate a new relationship without hesita-
tion or it may “save” their existing relationship.
Counseling should be conducted with the patient’s
partner, when possible to evaluate the partner’s
expectations for how the treatment will affect their
sexual relationship.
Ongoing communication between the sexual
medicine physician and the sex therapy mental
health practitioner provides the basis of the edu-
cation interventions that the mental health practi-
tioner presents to the patient about realistic
outcomes, potential side effects, and potential
adverse events. In settings in which mental health
practitioners and physicians are not within the
same clinic, a mental health practitioner may be
the initial contact for the patient experiencing
symptoms of PD. In this situation, the mental
health practitioner has the additional role of
guiding the patient with a referral to a urologist for
evaluation and consideration of medical treatment
of PD. It also may be important for mental health
practitioners to educate urologists in their area
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who may not be aware of the beneﬁt of sex therapy
in mental health services for the treatment of PD.
This can motivate physicians to encourage their
PD patients to get the mental health treatment
that they may need.
Conclusions
Sex therapy mental health practitioners and sexual
medicine physicians have key collaborative roles in
the integrated model of the clinical management
of patients with PD to maximize quality of life for
patients and their partners. Central to this inte-
grated and collaborative model is ongoing
communication between the mental health practi-
tioner and physician working with the patient with
PD about key assessments, treatment targets, and
treatment responses, allowing for coordinated
treatment planning and patient care. The mental
health practitioner in the integrated collaborative
care model is well positioned to assess patient
readiness for medical treatment of PD involving
surgery and to implement any needed interven-
tions to improve patient readiness. As a chronic,
progressive disease with uncertain outcome, PD
can result in signiﬁcant patient and partner distress
and relationship disruption. Loss of connection
and intimacy, lowered satisfaction in the sexual
relationship, and withdrawal of the partner from
the relationship are all meaningful targets for sex
therapy intervention. Sex therapy to improve self-
acceptance, learn new forms of sexual intimacy,
and improve communication with partners pro-
vides comprehensive treatment targeting emo-
tional, psychosexual, and relationship distress.
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